FDA gains oversight of compounding pharmacies; patients get safety labels.
S. 3794 — SAFE Drugs Act of 2026 · Filed by Jim Banks (R-IN) · 1 cosponsor · Introduced Feb 5, 2026 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires compounding pharmacies and physicians who send compounded drugs across state lines to report serious adverse events to the FDA and relevant states, and to file annual reports if they send more than 5% of their output interstate. It also mandates that compounded drugs carry labels stating they are not FDA-approved and include adverse-event reporting contact information. The bill tightens federal oversight of an industry that currently operates under lighter regulation than mass-manufactured pharmaceuticals.
Why we flagged it
The bill's operative mechanism is mandatory adverse-event reporting and labeling for compounded drugs sent across state lines. This is a regulatory tightening, not a deregulation or carve-out. It expands FDA and state oversight of an industry segment that previously had minimal federal reporting requirements.
What the text implies
- Compounding pharmacies and physicians may face increased compliance costs (systems for tracking, reporting, labeling), which could be passed to patients or reduce the economic viability of small compounding operations.
- The bill creates a federal-state information-sharing system, centralizing data on compounded-drug distribution; this may enable future enforcement actions or restrictions based on adverse-event patterns.
The full analysis lists 4 implications of this text.
Who stands to gain
FDA (expanded oversight authority and data collection); State pharmacy boards (expanded reporting and enforcement authority); Pharmaceutical manufacturers (potential competitive advantage if compounding becomes more costly or